Myomo's Q2 Beat: Margin Climb and Raised Guidance Point to Real Operating Progress

Q2 improved the story, but raised guidance is what raised the bar

Myomo's second quarter looked less like a one-off headline beat and more like a real operating improvement. The company posted $11.7 million in revenue against $10.29 million in consensus estimates, lost $0.09 per share versus a $0.10 per-share loss expected, and lifted Q3 2026 revenue guidance of $11.5 million to $12 million. It also raised its full-year outlook to $45 million to $47 million from $43 million to $46 million.

That changes the setup. Investors do not just have to accept a good quarter anymore; they have to judge whether Myomo can deliver against a higher guide.

The beat came with better operating leverage

This was not a messy win driven by extra spending. Gross margin expanded to 72.1% from 62.7%, while operating expenses rose less than 1%. That helped narrow the operating loss to $2.3 million from $4.6 million.

The more important point is that revenue growth and margin improvement came alongside restrained expense growth. For a small medical-device company, that is a more durable signal than a single quarter of stronger sales.

Cash is enough for execution, not for repeated mistakes

Myomo ended the quarter with $13.5 million in cash and short-term investments. That is enough runway to keep executing, but not enough to give management much room for a sloppy rollout.

If the raised guidance is met, this kind of operating progress can matter to the stock. If it is not, the same lean balance sheet makes the downside more painful.

Demand, mix, and process quality explain why the quarter mattered

The headline numbers were good, but the more useful read comes from the operating mix. Myomo did not just sell more units; the quarter also suggested the business is becoming a little easier to plan around.

Orders and backlog stayed healthy

Myomo took 255 MyoPro orders, up 23% from a year earlier, and finished the quarter with a 218-patient backlog even after delivering 211 units. That suggests demand was still building while shipments were already running.

Just as important, the quarter ended with 739 patients added during the quarter, up 2% sequentially. A rising pipeline is a better sign than a last-minute order spike if management expects the raised Q3 guide to hold.

Recurring patient sources are becoming more important

The clearest structural improvement was the source mix. Recurring patient sources represented 53% of total revenue, up from 26% a year earlier. Management said that milestone arrived roughly six months ahead of schedule.

If repeat referrals stay strong, revenue should get easier to predict quarter over quarter. If that share slips back toward the 26% level from a year ago, last quarter starts to look more like a good stretch than permanent proof of a better business model.

Revenue mix is shifting, but execution still matters

Myomo's revenue mix also changed. Medicare Part B patients accounted for 50% of Q2 revenue, down from 56% a year earlier, while Medicare Advantage fell from 20% to 16%. The VA rose to 3%. International revenue represented 17% of revenue, growing 32% year over year, and US O&P channel revenue represented 10%, growing 130%.

That broader mix can be read as progress: Myomo is becoming less dependent on any one payer lane. But it also raises the execution bar. Reimbursement and delivery still have to work cleanly, especially for a company selling expensive, customized devices.

Each unit still carries meaningful revenue

Myomo's average selling price of roughly $55,500 means the business depends on more than volume alone. Each sale has to move through verification, configuration, shipment, and installation without too much friction.

That helps explain why gross margin matters so much. If the process gets smoother, higher-unit growth can translate into much better operating leverage. If the process gets messy, the same model can stall quickly.

The next test is whether guidance turns into repeatable execution

Myomo does not need another sensational quarter to make a point. It needs to show that Q3 2026 revenue guidance of $11.5 million to $12 million is executable.

The main watch items are straightforward:

• Whether recurring patient sources stay above the low-50% range
• Whether the backlog converts into shipments and revenue smoothly
• Whether operating leverage holds as the company moves toward the higher full-year guide
• Whether reimbursement timing and channel growth stay balanced enough to support steady revenue recognition

The next hard proof point is Myomo's next financial results. Investors should focus less on relitigating Q2 and more on whether the operating trends keep showing up in the numbers.